Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 136-144

  Wang, Diping ^a   Lu, Ji ^a,b   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Androgen; Appoptosis; Prostate cancer; TRADD; TRAIL

Indexed keywords

ANDROGEN; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REGULATOR PROTEIN; RIP1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; MALE; METRIBOLONE; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TESTOSTERONE CONGENERS; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878461467     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.001     Document Type: Article

References (39)

1. Tang D.G., Porter A.T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997, 32:284-293.
2. Hesry V., Piquet-Pellorce C., Travert M., Donaghy L., Jegou B., Patard J.J., Guillaudeux T. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006, 66:987-995.
3. Nakajima Y., DelliPizzi A.M., Mallouh C., Ferreri N.R. TNF-mediated cytotoxicity and resistance in human prostate cancer cell lines. Prostate 1996, 29:296-302.
4. Koschny R., Walczak H., Ganten T.M. The promise of TRAIL - potential and risks of a novel anticancer therapy. J. Mol. Med. (Berl.) 2007, 85:923-935.
5. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
6. Thorburn A., Behbakht K., Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist. Update 2008, 11:17-24.
7. Bucur O., Ray S., Bucur M.C., Almasan A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci. 2006, 11:1549-1568.
8. Schug Z.T., Gonzalvez F., Houtkooper R.H., Vaz F.M., Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ. 2011, 18:538-548.
9. Ray S., Bucur O., Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005, 10:1411-1418.
10. Munshi A., Pappas G., Honda T., McDonnell T.J., Younes A., Li Y., Meyn R.E. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 2001, 20:3757-3765.
11. Nesterov A., Lu X., Johnson M., Miller G.J., Ivashchenko Y., Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 2001, 276:10767-10774.
12. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., Srivastava R.K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001, 20:6073-6083.
13. Thakkar H., Chen X., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., Srivastava R.K. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem. 2001, 276:38361-38369.
14. Beresford S.A., Davies M.A., Gallick G.E., Donato N.J. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J. Interferon Cytokine Res. 2001, 21:313-322.
15. Dieterle A., Orth R., Daubrawa M., Grotemeier A., Alers S., Ullrich S., Lammers R., Wesselborg S., Stork B. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int. J. Cancer 2009, 125:932-941.
16. Seol J.W., Lee Y.J., Kang H.S., Kim I.S., Kim N.S., Kwak Y.G., Kim T.H., Seol D.W., Park S.Y. Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein. Exp. Oncol. 2005, 27:120-124.
17. Rokhlin O.W., Taghiyev A.F., Guseva N.V., Glover R.A., Syrbu S.I., Cohen M.B. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol. Ther. 2002, 1:631-637.
18. Vindrieux D., Reveiller M., Chantepie J., Yakoub S., Deschildre C., Ruffion A., Devonec M., Benahmed M., Grataroli R. Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell. Int. 2011, 11:42.
19. Rokhlin O.W., Taghiyev A.F., Guseva N.V., Glover R.A., Chumakov P.M., Kravchenko J.E., Cohen M.B. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005, 24:6773-6784.
20. Raclaw K.A., Heemers H.V., Kidd E.M., Dehm S.M., Tindall D.J. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate 2008, 68:1696-1706.
21. Cornforth A.N., Davis J.S., Khanifar E., Nastiuk K.L., Krolewski J.J. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 2008, 27:4422-4433.
22. Dehm S.M., Tindall D.J. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J. Biol. Chem. 2006, 281:27882-27893.
23. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
24. Wang D., Montgomery R.B., Schmidt L.J., Mostaghel E.A., Huang H., Nelson P.S., Tindall D.J. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009, 69:9448-9456.
25. Mitterberger M., Neuwirt H., Cavarretta I.T., Hobisch A., Culig Z. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide. Prostate 2007, 67:1194-1201.
26. Zhang X., Li W., Olumi A.F. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin. Cancer Res. 2007, 13:7181-7190.
27. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., Pai R., Hymowitz S.G., Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 2005, 280:2205-2212.
28. Kim J.Y., Lee J.Y., Kim D.G., Koo G.B., Yu J.W., Kim Y.S. TRADD is critical for resistance to TRAIL-induced cell death through NF-kappaB activation. FEBS Lett. 2011, 585:2144-2150.
29. Zheng L., Bidere N., Staudt D., Cubre A., Orenstein J., Chan F.K., Lenardo M. Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol. Cell. Biol. 2006, 26:3505-3513.
30. Kimura K., Markowski M., Bowen C., Gelmann E.P. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 2001, 61:5611-5618.
31. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
32. Eid M.A., Lewis R.W., Abdel-Mageed A.B., Kumar M.V. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation. Int. J. Oncol. 2002, 21:111-117.
33. Deeb D., Jiang H., Gao X., Hafner M.S., Wong H., Divine G., Chapman R.A., Dulchavsky S.A., Gautam S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 2004, 3:803-812.
34. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995, 81:495-504.
35. Yount G.L., Afshar G., Ries S., Korn M., Shalev N., Basila D., McCormick F., Haas-Kogan D.A. Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells. Oncogene 2001, 20:2826-2835.
36. Cao X., Pobezinskaya Y.L., Morgan M.J., Liu Z.G. The role of TRADD in TRAIL-induced apoptosis and signaling. Faseb J. 2011, 25:1353-1358.
37. Gao S., Lee P., Wang H., Gerald W., Adler M., Zhang L., Wang Y.F., Wang Z. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol. Endocrinol. 2005, 19:1792-1802.
38. Chakravarti A., Zhai G.G., Zhang M., Malhotra R., Latham D.E., Delaney M.A., Robe P., Nestler U., Song Q., Loeffler J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23:7494-7506.
39. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.